Diabetic Kidney DiseaseNCT06578325
Effects of Thai Dance Meditation Exercise on Renal and Cerebrovascular Function in Elderly With Diabetic Kidney Disease
A study testing Thai dance meditation in people with Diabetic Kidney Disease, run by Chulalongkorn University at 1 site in Thailand.
Trial summary
Elderly with diabetic kidney disease who practiced Thai dance meditation training more favorable adaptations than normal daily life in improving glycemic control, kidney function, vascular function and cerebrovascular function. Read more about this study
- Who is it for?
- Ages 60 to 75 years
- Conditions the study is for
- Diabetic Kidney Disease
- What is being tested?
- Thai dance meditation
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 40 participants
- Where
- 1 siteThailand
- Study dates
- 15 Aug 2021to 31 Jul 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 60 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- The inclusion criteria included diabetic kidney disease (DKD) (as defined by the KDIGO (Kidney Disease Improving Global Outcomes 2012), a baseline glycosylated hemoglobin (HbA1c) value of 7-9%, albumin-to creatinine ratio (ACR): A3 [>300 mg/day; ACR, >300 mg/g (>30 mg/mmol)], GFR category 3 (moderately decreased) has now been divided into categories G3a [45-59 mL/ min1 /(1.73m2) and G3b [30 -44 mL/ min1/(1.73 m2) which represent mildly to moderately decreased function and moderately to severely decreased function and no previous exercise training in the past 6 months.
- All participants were free from diabetic retinopathy, severe diabetic neurophathy, severe cardiovascular and cerebrovascular diseases.
- Participants had Montreal Cognitive Assessment - Thai (MoCa-T) scores between 18 24 points.
- Not having uncontrolled high blood pressure (Systolic blood pressure; SBP) >159 mmHg and Diastolic blood pressure; DBP) > 99 mmHg
Who cannot join
- Participants were excluded if they dropped out or completed less than 80% of the training schedule
Trial locations and contacts
1 site in 1 country.
Thailand1 site
Faculty of Sports Science, Chulalongkorn University
Pathum Wan, Bangkok, 10330
About this study
Elderly with diabetic kidney disease who practiced Thai dance meditation training more favorable adaptations than normal daily life in improving glycemic control, kidney function, vascular function and cerebrovascular function.
Read the detailed description
This cross-sectional study was to compare glycemic control, kidney function, vascular function, cerebrovascular function, physical fitness and quality of life between elderly with diabetic kidney disease who practiced Thai dance meditation training and normal daily life.
- Conditions
- Diabetic Kidney Disease
- Being tested
- Thai dance meditation, No intervention
- Keywords
- Diabetic kidney disease, Cerebrovascular reactivity, Renal function, Thai dance meditation
- Medical subject headings
- Diabetic Nephropathies
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Thai dance meditationOther
Thai dance meditation training program will be based on aerobic Thai dance exercise combined with Buddhist meditation. The participants will perform aerobic Thai dance meditation while concentrated on hand movements through counting the numbers 1 2 3 4 5 6 7 1 on the 1st round and continuing on the 2nd round, counting as 1 2 3 4 5 6 7 2…. Repeat for 8 rounds. Thai dance meditation will be conducted at mild to moderate intensity (40-60% heart rate reserve) and in phase 2 (week 7-12), the training intensity will be increased to moderate intensity (50-60% heart rate reserve). In both phases the training will be performed foe 50 minutes, 3 times per week.
No interventionOther
No intervention
| Study group | Role | What they receive |
|---|---|---|
| Diabetes kidney disease patients with Thai dance meditation | Experimental | Male and female diabetic kidney disease patients were selected based on screening for diabetes and renal function. They were recruited for measurement of all variables in the study to compare with another group. Receives: Other: Thai dance meditation |
| Diabetes kidney disease patients | Sham comparator | Male and female diabetic kidney disease patients were not training Thai dance meditation. They were recruited for measurement of all variables in the study to compare with another group. Receives: Other: No intervention |
What is being measured
The primary outcome is the main question the study is designed to answer.
Blood pressure
Blood pressure (systolic blood pressure, diastolic blood pressure, and mean arterial pressure) in mmHg will be measured with automated blood pressure in mmHg device (CARESCAPE V100, GE Dinamap).
Measured: Change from baseline systolic blood pressure, diastolic blood pressure, and mean arterial pressure at 12 weeks.]
Heart rate
Heart rate in beats per minute will be measured with automated blood pressure in beat per minute device (CARESCAPE V100, GE Dina map).
Measured: Change from baseline heart rate at 12 weeks
Body fat
Body fat in percent will be measured with dual energy x-ray absorptiometry in percent (Prodigy-Pro, GE healthcare).
Measured: Change from baseline body fat at 12 weeks
Muscle mass and Weight
Muscle mass and weight in kilograms will be measured with dual energy x-ray absorptiometry in kilogram (Prodigy-Pro, GE healthcare).
Measured: Change from baseline muscle mass and weight at 12 weeks.
Arterial stiffness
Arterial stiffness will be measured with brachial-ankle pulse wave velocity in centimeter per second (VP-1000 plus, omrom Healthcare).
Measured: Change from baseline brachial-ankle pulse wave velocity at 12 weeks
Macro vascular function
Macro vascular function will be measured by brachial artery flow-mediated dilatation in percent with ultrasonography equipment EPIQ 5G, Phillips.
Measured: Change from baseline brachial artery flow-mediated dilatation at 12 weeks
Renal function
Blood urea nitrogen (BUN) in milligram per deciliter will be measure by Kinetic test with urease and glutamate dehydrogenase with urease/glutamate dehydrogenase coupled enzymatic (Coupled enzymes)
Measured: Change from baseline Blood urea nitrogen at 12 weeks.
Intrarenal artery
Intrarenal artery will be measured by renal blood flow in renal arterial resistive index (RI) with ultrasonography equipment EPIQ 5G, Phillips.
Measured: Change from baseline renal arterial resistive index (RI) at 12 weeks.
Post Occlusive Reactive Hyperemia; PORH
Evaluation of blood flow to the skin area in percent will be measured by Post Occlusive Reactive Hyperemia in percent; PORH with Laser Doppler flowmeter, Perimed AB, Sweden.
Measured: Change from baseline Post Occlusive Reactive Hyperemia; PORH at 12 weeks.
Cerebral blood flow
Cerebral blood flow in centimeter per second will be measure with ultrasonography equipment (EPIQ 5G, Phillips).
Measured: Change from baseline cerebral blood flow at 12 weeks
Cerebrovascular conductance index
Cerebrovascular conductance index in cm/sec/mmHg will be measured with ultrasonography equipment (EPIQ 5G, Phillips).
Measured: Change from baseline cerebrovascular conductance index at 12 weeks
Cerebrovascular reactivity index
Cerebrovascular reactivity index in %cm/sec/mmHg will be measured with ultrasonography equipment (EPIQ 5G, Phillips).
Measured: Change from baseline cerebrovascular reactivity index at 12 weeks
Arterial compliance
Arterial compliance in units will be measure by carotid diameter during systolic and diastolic with ultrasonography equipment (EPIQ 5G, Phillips) and systemic blood pressure with (VP-1000 plus, omrom Healthcare).
Measured: Change from baseline Arterial compliance at 12 weeks
Pulsatility index
Pulsatility index in units will be measure with ultrasonography equipment (EPIQ 5G, Phillips).
Measured: Change from baseline Pulsatility index at 12 weeks.] 12.Montreal Cognitive Assessment
Montreal Cognitive Assessment
Montreal Cognitive Assessment in score (0 - 30 scores) cut off below 25 scores that indicate impairment cognitive function.
Measured: Change from baseline Montreal Cognitive Assessment at 12 weeks.]
Mini-Mental State Examination
Mini-Mental State Examination in scores (0 - 30 scores) cut off below 25 scores that indicate impairment cognitive function.
Measured: Change from baseline Mini-Mental State Examination at 12 weeks.]
Trail Making Test-B
Trail Making Test-B in second cut off below 101 seconds that indicate dementia.
Measured: Change from baseline Trail Making Test-B at 12 weeks
Fasting blood sugar
Fasting blood sugar in mg/dl will be measure with enzymatic assay using hexokinase reaction.
Measured: Change from baseline fasting blood sugar at 12 weeks.]
Glycosylated hemoglobin
Glycosylated hemoglobin in percent will be measure with enzymatic assay using hexokinase reaction.
Measured: Change from baseline Glycosylated hemoglobin at 12 weeks.]
Homeostasis Model Assessment of insulin resistance
Homeostasis Model Assessment of insulin resistance in units will be calculated with Fasting blood sugar and insulin.
Measured: Change from baseline Homeostasis Model Assessment of insulin resistance at 12 weeks.]
Creatinine
Creatinine in mg/dl will be measure with enzymatic assay
Measured: Change from baseline creatinine at 12 weeks.]
estimate Glomerular filtration rate
estimate Glomerular filtration rate in ml/min/1.73 m2 will be calculated by CKD-EPI formular according to National kidney foundation recommendation.
Measured: Change from baseline estimate Glomerular filtration rate at 12 weeks.]
Cystatin C
Cystatin C in mg/L will be measure with particle enhanced Immunoturbidimetric assay
Measured: Change from baseline blood urea nitrogen at 12 weeks
Urine albumin creatinine ratio
Urine albumin creatinine ratio will be measure with Immunoturbidimetric assay
Measured: Change from baseline urine albumin creatinine ratio at 12 weeks.
Stroop test
Stroop test in second will be measured with EncephalApp - Stroop Test
Measured: Change from baseline Stroop test in second at 12 weeks.
Secondary outcomes (13)
Waist circumference
Waist circumference in inch will be measure by waist tape
Measured: Change from baseline waist circumference at 12 weeks]
.Flexibility testing
Flexibility testing will be measure by Chair sit \& reach protocol in centimeters.
Measured: Change from baseline Chair sit & reach at 12 weeks.]
Muscle strength testing
Muscle strength testing will be measured by arm-curl test repetitions in 30 seconds
Measured: Change from baseline arm-curl and chair stand at 12 weeks.]
Muscle strength testing
Muscle strength testing will be measured by arm-curl test and chair stand test in repetitions in 30 seconds
Measured: Change from baseline arm-curl and chair stand at 12 weeks.]
Balance testing
Balance testing will be measured by time up and go testing in seconds.
Measured: Change from baseline time up and go at 12 weeks.]
Cardiopulmonary fitness
Cardiopulmonary fitness will be measure by 6-minutes walk test in meters.
Measured: Change from baseline 6-minutes walk at 12 weeks.]
Lipid profile
Lipid profile will be measure by cholesterol, triglyceride, high density lipoprotein, and low density lipoprotein in mg/dl.
Measured: Change from baseline Nitric oxide at 12 weeks.] cholesterol, triglyceride, high density lipoprotein, and low density lipoprotein at 12 weeks.]
Interleukin-6 (IL-6), Tumor necrosis factor-alpha (TNF- α), Brain derived neurotrophic factor, Malondialdehyde, Superoxide Dismutase.
Interleukin-6 (IL-6), Tumor necrosis factor-alpha (TNF- α), Brain derived neurotrophic factor, Malondialdehyde, Superoxide Dismutase in pg/ml will be measure with ELISA assay kit.
Measured: Change from baselineInterleukin-6 (IL-6), Tumor necrosis factor-alpha (TNF- α), Brain derived neurotrophic factor, Malondialdehyde, Superoxide Dismutase. at 12 weeks.]
Nitric oxide
Nitric oxide in µM will measured with standard Griess reagents.
Measured: Change from baseline Nitric oxide at 12 weeks.
Quality of life in patients with chronic kidney disease
Quality of life will be measured by SF-36 questionnaire for evaluation of Quality of Life in patients with chronic kidney disease. The scores of questionnaires were 75-100 points for good quality of life, 50-75 points for moderate quality of life, 25-50 points for low quality of life and 0-25 points for very low quality of life.
Measured: Change from baseline at 12 weeks.
Flexibility testing
Flexibility testing will be measure by back scratch in centimeters.
Measured: Change from baseline back scratch at 12 weeks.
Muscle strength testing
Muscle strength testing will be measured by chair stand test in repetitions in 30 seconds
Measured: Change from baseline chair stand at 12 weeks.]
Body mass index (BMI)
Body mass index (BMI) through height and weight measurement by body composition analyzer weight and height will be combined to report BMI in kg/m^2.
Measured: Change from baseline BMI at 12 weeks.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Aug 2024
- Study start15 Aug 2021
- Primary completion30 Jun 2022
- Study completion31 Jul 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Diabetic Kidney DiseaseStudies of the same condition, open and under way.
- More trials run by Chulalongkorn UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 40 participants (actual)
Sponsor and investigators
- Lead sponsor
- Chulalongkorn University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Prof. Dr.Daroonwan Suksom, Chulalongkorn University
- Investigators
- Daroonwan Suksom, Ph.D., Principal investigator, Chulalongkorn University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06578325
- Sponsor's protocol ID
- SPSC-9
- Status last verified
- Aug 2024
- First submitted
- 18 Aug 2024
- Last updated
- 29 Aug 2024
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 Aug 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Thai Dance Meditation Exercise on Renal and Cerebrovascular Function in Elderly With Diabetic Kidney Disease
- ClinicalTrials.gov ID
- NCT06578325
- Acronym / sponsor ID
- SPSC-9
- Conditions
- Diabetic Kidney Disease
- Keywords
- Diabetic kidney disease, Cerebrovascular reactivity, Renal function, Thai dance meditation
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 40 participants (actual)
- Lead sponsor
- Chulalongkorn UniversityUniversity, hospital or other
- Study start
- 15 Aug 2021 (actual)
- Primary completion
- 30 Jun 2022 (actual)
- Study completion
- 31 Jul 2022 (actual)
- First posted
- 29 Aug 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Elderly with diabetic kidney disease who practiced Thai dance meditation training more favorable adaptations than normal daily life in improving glycemic control, kidney function, vascular function and cerebrovascular function.
Detailed description
This cross-sectional study was to compare glycemic control, kidney function, vascular function, cerebrovascular function, physical fitness and quality of life between elderly with diabetic kidney disease who practiced Thai dance meditation training and normal daily life.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Diabetes kidney disease patients with Thai dance meditation | Experimental | Other: Thai dance meditationMale and female diabetic kidney disease patients were selected based on screening for diabetes and renal function. They were recruited for measurement of all variables in the study to compare with another group. |
| Diabetes kidney disease patients | Sham comparator | Other: No interventionMale and female diabetic kidney disease patients were not training Thai dance meditation. They were recruited for measurement of all variables in the study to compare with another group. |
Who may qualify
- Ages
- 60 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- The inclusion criteria included diabetic kidney disease (DKD) (as defined by the KDIGO (Kidney Disease Improving Global Outcomes 2012), a baseline glycosylated hemoglobin (HbA1c) value of 7-9%, albumin-to creatinine ratio (ACR): A3 [>300 mg/day; ACR, >300 mg/g (>30 mg/mmol)], GFR category 3 (moderately decreased) has now been divided into categories G3a [45-59 mL/ min1 /(1.73m2) and G3b [30 -44 mL/ min1/(1.73 m2) which represent mildly to moderately decreased function and moderately to severely decreased function and no previous exercise training in the past 6 months.
- All participants were free from diabetic retinopathy, severe diabetic neurophathy, severe cardiovascular and cerebrovascular diseases.
- Participants had Montreal Cognitive Assessment - Thai (MoCa-T) scores between 18 24 points.
- Not having uncontrolled high blood pressure (Systolic blood pressure; SBP) >159 mmHg and Diastolic blood pressure; DBP) > 99 mmHg
Key exclusion criteria (1 listed)
- Participants were excluded if they dropped out or completed less than 80% of the training schedule
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Thai dance meditationThai dance meditation training program will be based on aerobic Thai dance exercise combined with Buddhist meditation. The participants will perform aerobic Thai dance meditation while concentrated on hand movements through counting the numbers 1 2 3 4 5 6 7 1 on the 1st round and continuing on the 2nd round, counting as 1 2 3 4 5 6 7 2…. Repeat for 8 rounds. Thai dance meditation will be conducted at mild to moderate intensity (40-60% heart rate reserve) and in phase 2 (week 7-12), the training intensity will be increased to moderate intensity (50-60% heart rate reserve). In both phases the training will be performed foe 50 minutes, 3 times per week. | Other | Diabetes kidney disease patients with Thai dance meditation |
| No interventionNo intervention | Other | Diabetes kidney disease patients |
Primary outcome
Blood pressure
Time frame: Change from baseline systolic blood pressure, diastolic blood pressure, and mean arterial pressure at 12 weeks.]
Blood pressure (systolic blood pressure, diastolic blood pressure, and mean arterial pressure) in mmHg will be measured with automated blood pressure in mmHg device (CARESCAPE V100, GE Dinamap).
Heart rate
Time frame: Change from baseline heart rate at 12 weeks
Heart rate in beats per minute will be measured with automated blood pressure in beat per minute device (CARESCAPE V100, GE Dina map).
Body fat
Time frame: Change from baseline body fat at 12 weeks
Body fat in percent will be measured with dual energy x-ray absorptiometry in percent (Prodigy-Pro, GE healthcare).
Muscle mass and Weight
Time frame: Change from baseline muscle mass and weight at 12 weeks.
Muscle mass and weight in kilograms will be measured with dual energy x-ray absorptiometry in kilogram (Prodigy-Pro, GE healthcare).
Arterial stiffness
Time frame: Change from baseline brachial-ankle pulse wave velocity at 12 weeks
Arterial stiffness will be measured with brachial-ankle pulse wave velocity in centimeter per second (VP-1000 plus, omrom Healthcare).
Macro vascular function
Time frame: Change from baseline brachial artery flow-mediated dilatation at 12 weeks
Macro vascular function will be measured by brachial artery flow-mediated dilatation in percent with ultrasonography equipment EPIQ 5G, Phillips.
Renal function
Time frame: Change from baseline Blood urea nitrogen at 12 weeks.
Blood urea nitrogen (BUN) in milligram per deciliter will be measure by Kinetic test with urease and glutamate dehydrogenase with urease/glutamate dehydrogenase coupled enzymatic (Coupled enzymes)
Intrarenal artery
Time frame: Change from baseline renal arterial resistive index (RI) at 12 weeks.
Intrarenal artery will be measured by renal blood flow in renal arterial resistive index (RI) with ultrasonography equipment EPIQ 5G, Phillips.
Post Occlusive Reactive Hyperemia; PORH
Time frame: Change from baseline Post Occlusive Reactive Hyperemia; PORH at 12 weeks.
Evaluation of blood flow to the skin area in percent will be measured by Post Occlusive Reactive Hyperemia in percent; PORH with Laser Doppler flowmeter, Perimed AB, Sweden.
Cerebral blood flow
Time frame: Change from baseline cerebral blood flow at 12 weeks
Cerebral blood flow in centimeter per second will be measure with ultrasonography equipment (EPIQ 5G, Phillips).
Cerebrovascular conductance index
Time frame: Change from baseline cerebrovascular conductance index at 12 weeks
Cerebrovascular conductance index in cm/sec/mmHg will be measured with ultrasonography equipment (EPIQ 5G, Phillips).
Cerebrovascular reactivity index
Time frame: Change from baseline cerebrovascular reactivity index at 12 weeks
Cerebrovascular reactivity index in %cm/sec/mmHg will be measured with ultrasonography equipment (EPIQ 5G, Phillips).
Arterial compliance
Time frame: Change from baseline Arterial compliance at 12 weeks
Arterial compliance in units will be measure by carotid diameter during systolic and diastolic with ultrasonography equipment (EPIQ 5G, Phillips) and systemic blood pressure with (VP-1000 plus, omrom Healthcare).
Pulsatility index
Time frame: Change from baseline Pulsatility index at 12 weeks.] 12.Montreal Cognitive Assessment
Pulsatility index in units will be measure with ultrasonography equipment (EPIQ 5G, Phillips).
Montreal Cognitive Assessment
Time frame: Change from baseline Montreal Cognitive Assessment at 12 weeks.]
Montreal Cognitive Assessment in score (0 - 30 scores) cut off below 25 scores that indicate impairment cognitive function.
Mini-Mental State Examination
Time frame: Change from baseline Mini-Mental State Examination at 12 weeks.]
Mini-Mental State Examination in scores (0 - 30 scores) cut off below 25 scores that indicate impairment cognitive function.
Trail Making Test-B
Time frame: Change from baseline Trail Making Test-B at 12 weeks
Trail Making Test-B in second cut off below 101 seconds that indicate dementia.
Fasting blood sugar
Time frame: Change from baseline fasting blood sugar at 12 weeks.]
Fasting blood sugar in mg/dl will be measure with enzymatic assay using hexokinase reaction.
Glycosylated hemoglobin
Time frame: Change from baseline Glycosylated hemoglobin at 12 weeks.]
Glycosylated hemoglobin in percent will be measure with enzymatic assay using hexokinase reaction.
Homeostasis Model Assessment of insulin resistance
Time frame: Change from baseline Homeostasis Model Assessment of insulin resistance at 12 weeks.]
Homeostasis Model Assessment of insulin resistance in units will be calculated with Fasting blood sugar and insulin.
Creatinine
Time frame: Change from baseline creatinine at 12 weeks.]
Creatinine in mg/dl will be measure with enzymatic assay
estimate Glomerular filtration rate
Time frame: Change from baseline estimate Glomerular filtration rate at 12 weeks.]
estimate Glomerular filtration rate in ml/min/1.73 m2 will be calculated by CKD-EPI formular according to National kidney foundation recommendation.
Cystatin C
Time frame: Change from baseline blood urea nitrogen at 12 weeks
Cystatin C in mg/L will be measure with particle enhanced Immunoturbidimetric assay
Urine albumin creatinine ratio
Time frame: Change from baseline urine albumin creatinine ratio at 12 weeks.
Urine albumin creatinine ratio will be measure with Immunoturbidimetric assay
Stroop test
Time frame: Change from baseline Stroop test in second at 12 weeks.
Stroop test in second will be measured with EncephalApp - Stroop Test
13 secondary outcomes
Waist circumference
Time frame: Change from baseline waist circumference at 12 weeks]
.Flexibility testing
Time frame: Change from baseline Chair sit & reach at 12 weeks.]
Muscle strength testing
Time frame: Change from baseline arm-curl and chair stand at 12 weeks.]
Muscle strength testing
Time frame: Change from baseline arm-curl and chair stand at 12 weeks.]
Balance testing
Time frame: Change from baseline time up and go at 12 weeks.]
Cardiopulmonary fitness
Time frame: Change from baseline 6-minutes walk at 12 weeks.]
Lipid profile
Time frame: Change from baseline Nitric oxide at 12 weeks.] cholesterol, triglyceride, high density lipoprotein, and low density lipoprotein at 12 weeks.]
Interleukin-6 (IL-6), Tumor necrosis factor-alpha (TNF- α), Brain derived neurotrophic factor, Malondialdehyde, Superoxide Dismutase.
Time frame: Change from baselineInterleukin-6 (IL-6), Tumor necrosis factor-alpha (TNF- α), Brain derived neurotrophic factor, Malondialdehyde, Superoxide Dismutase. at 12 weeks.]
Nitric oxide
Time frame: Change from baseline Nitric oxide at 12 weeks.
Quality of life in patients with chronic kidney disease
Time frame: Change from baseline at 12 weeks.
Flexibility testing
Time frame: Change from baseline back scratch at 12 weeks.
Muscle strength testing
Time frame: Change from baseline chair stand at 12 weeks.]
Body mass index (BMI)
Time frame: Change from baseline BMI at 12 weeks.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Aug 2024.
- Individual participant dataSharing planned: No
Related trials for Diabetic Kidney Disease
Not yet recruitingObservational study
Beta-2-Trace Protein in Diabetic Nephropathy
Diabetic Nephropathy Type 2, Type 2 Diabetes Mellitus
Active, not recruitingObservational study
Family Investigation of Nephropathy and Diabetes (F.I.N.D.)
Diabetic Nephropathy, Diabetes Mellitus
Active, not recruitingPhase 4
Pentoxifylline in Diabetic Kidney Disease
Diabetic Kidney Disease
Active, not recruitingPhase 2
A Study on the Safety and Clinical Efficacy of Guominkang in the Treatment of Diabetic Kidney Disease
Diabetic Kidney Disease (DKD), Type 2 Diabetes
Not yet recruitingObservational study
Relationship Between Insulin Dose and Complications in Type 1 Diabetes
Diabetes Mellitus, Type 1 Diabetes, Cardiovascular Diseases (CVD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Daroonwan Suksom, Ph.D. principal investigator
Chulalongkorn University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Thai dance meditation in people with Diabetic Kidney Disease, run by Chulalongkorn University at 1 site in Thailand.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 29 Aug 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Thailand. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Blood pressure (time frame: Change from baseline systolic blood pressure, diastolic blood pressure, and mean arterial pressure at 12 weeks.]). The study lists 25 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Aug 2024.